

Morten Schou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4440747/publications.pdf>

Version: 2024-02-01

41
papers

4,871
citations

567281

15
h-index

414414

32
g-index

43
all docs

43
docs citations

43
times ranked

5582
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
2	Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. <i>European Journal of Heart Failure</i> , 2016, 18, 260-266.	7.1	158
3	Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	27.0	130
4	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 106-116.	11.4	80
5	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
6	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. <i>PLoS ONE</i> , 2016, 11, e0157167.	2.5	42
7	Prevalence and significance of troponin elevations in patients without acute coronary disease. <i>International Journal of Cardiology</i> , 2016, 222, 819-825.	1.7	33
8	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
9	Î±-Defensins and outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 387-394.	7.1	22
10	Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: <scp>NorthStar</scp> Adherence Study. <i>European Journal of Heart Failure</i> , 2014, 16, 1249-1255.	7.1	21
11	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 117.	1.7	21
12	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). <i>American Heart Journal</i> , 2021, 231, 137-146.	2.7	21
13	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. <i>International Journal of Cardiology</i> , 2015, 195, 143-148.	1.7	20
14	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
15	<p>Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 589-594.	3.0	17
16	Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. <i>International Journal of Cardiology</i> , 2016, 221, 944-950.	1.7	12
17	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	3.7	12
18	Sex-Specific Prevalence, Incidence, and Mortality Associated With Atrial Fibrillation in Heart Failure. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1366-1375.	3.2	10

#	ARTICLE	IF	CITATIONS
19	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2021, 14, e008662.	3.9	10
20	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). <i>Cardiovascular Diabetology</i> , 2022, 21, 34.	6.8	10
21	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , 2021, 143, 2208-2210.	1.6	8
22	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. <i>International Journal of Cardiology</i> , 2014, 177, 942-948.	1.7	6
23	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	1.5	6
24	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. <i>Journal of Cardiac Failure</i> , 2015, 21, 250-257.	1.7	5
25	Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. <i>IJC Heart and Vasculature</i> , 2022, 41, 101065.	1.1	5
26	Rate of Heart Failure Following Atrial Fibrillation According to Presence of Family History of Dilated Cardiomyopathy or Heart Failure: A Nationwide Study. <i>Journal of the American Heart Association</i> , 2021, 10, e021286.	3.7	4
27	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	1.9	3
28	The effect of heparin on pregnancy associated plasma protein-A concentration in healthy, non-pregnant individuals. <i>Clinical Biochemistry</i> , 2015, 48, 757-761.	1.9	2
29	Long-term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e021310.	3.7	2
30	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. <i>Journal of the American Heart Association</i> , 2021, 10, e021230.	3.7	2
31	Sodium-glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, , .	2.5	1
32	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. <i>American Heart Journal</i> , 2022, 250, 57-57.	2.7	1
33	Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score. <i>Open Heart</i> , 2020, 7, e001380.	2.3	0
34	Abstract P058: Risk Of Heart Failure In Type 2 Diabetes Has Decreased Over Time - A Danish Nationwide Cohort Study. <i>Circulation</i> , 2021, 143, .	1.6	0
35	Abstract 16546: Pre-Pregnancy Body Mass Index and Risk of Peripartum Cardiomyopathy and Heart Failure in the Years Following Delivery. <i>Circulation</i> , 2020, 142, .	1.6	0
36	Abstract 10837: Prognostic Importance of Atrial Fibrillation in Heart Failure According to Time Elapsed Since Diagnosis. <i>Circulation</i> , 2021, 144, .	1.6	0

#	ARTICLE	IF	CITATIONS
37	Abstract 10629: Effect of Empagliflozin on Blood Volume Redistribution in Patients with Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2021, 144, .	1.6	0
38	Abstract 10875: Long-Term Mortality Associated with Use of Carvedilol vs Metoprolol in Heart Failure Patients with and Without Type 2 Diabetes. <i>Circulation</i> , 2021, 144, .	1.6	0
39	Abstract 10903: Cardiovascular Morbidity Associated with Monoclonal Gammopathy of Undetermined Significance - A Danish Nationwide Study. <i>Circulation</i> , 2021, 144, .	1.6	0
40	MO466: Impact of Renal Insufficiency on Choice of Rhythm or Rate Control in Atrial Fibrillation and Subsequent Effects on Cardiovascular and Mortality Outcomes. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
41	MO445: Implications of Cardiac Biomarkers in Patients With Renal Insufficiency on Probability of Coronary Angiography and Subsequent Cardiovascular Outcomes. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0